Truvestments Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $37.6K | Hold |
299
| – | – | 0.01% | 442 |
|
|
2025
Q1 | $33.1K | Sell |
299
-259
| -46% | -$28.6K | 0.01% | 471 |
|
|
2024
Q4 | $76.2K | Buy |
558
+14
| +3% | +$1.91K | 0.02% | 312 |
|
|
2024
Q3 | $62.7K | Buy |
+544
| New | +$62.7K | 0.02% | 333 |
|
|
2024
Q2 | – | Sell |
-566
| Closed | -$78.1K | – | 511 |
|
|
2024
Q1 | $78.1K | Buy |
566
+298
| +111% | +$41.1K | 0.03% | 311 |
|
|
2023
Q4 | $35.3K | Hold |
268
| – | – | 0.02% | 362 |
|
|
2023
Q3 | $30.2K | Hold |
268
| – | – | 0.02% | 338 |
|
|
2023
Q2 | $25.3K | Hold |
268
| – | – | 0.01% | 358 |
|
|
2023
Q1 | $27.1K | Hold |
268
| – | – | 0.01% | 348 |
|
|
2022
Q4 | $32K | Sell |
268
-845
| -76% | -$101K | 0.02% | 341 |
|
|
2022
Q3 | $118K | Hold |
1,113
| – | – | 0.07% | 190 |
|
|
2022
Q2 | $108K | Buy |
+1,113
| New | +$108K | 0.06% | 200 |
|
|
2022
Q1 | – | Sell |
-1,226
| Closed | -$104K | – | 404 |
|
|
2021
Q4 | $104K | Buy |
1,226
+195
| +19% | +$16.5K | 0.05% | 208 |
|
|
2021
Q3 | $99K | Buy |
1,031
+34
| +3% | +$3.27K | 0.05% | 201 |
|
|
2021
Q2 | $97K | Buy |
997
+224
| +29% | +$21.8K | 0.05% | 202 |
|
|
2021
Q1 | $75K | Buy |
773
+495
| +178% | +$48K | 0.04% | 241 |
|
|
2020
Q4 | $26K | Buy |
+278
| New | +$26K | 0.02% | 327 |
|
|
2020
Q3 | – | Sell |
-80
| Closed | -$9K | – | 463 |
|
|
2020
Q2 | $9K | Buy |
80
+11
| +16% | +$1.24K | 0.01% | 387 |
|
|
2020
Q1 | $5K | Buy |
+69
| New | +$5K | 0.01% | 418 |
|
|
2019
Q4 | – | Sell |
-38
| Closed | -$3K | – | 420 |
|
|
2019
Q3 | $3K | Buy |
+38
| New | +$3K | ﹤0.01% | 638 |
|